Tofacitinib for Immune Skin Conditions in Down Syndrome
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
People with Down syndrome (DS) display widespread immune dysregulation, including several
immune skin conditions. This study hypothesizes that pharmacological inhibition of the
increased interferon (IFN) signaling seen in DS is safe and could improve associated skin
conditions.
The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug
known to block IFN signaling, in adolescents and adults with DS and an autoimmune and/or
autoinflammatory skin condition. Investigators will also measure the impact of interferon
inhibition on a variety of molecular markers, as well as the cognitive abilities and quality
of life of participants.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)